Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Pharmacogenetic investigation of response to duloxetine treatment in generalized anxiety disorder.

Perlis RH, Fijal B, Dharia S, Houston JP.

Pharmacogenomics J. 2013 Jun;13(3):280-5. doi: 10.1038/tpj.2011.62. Epub 2012 Jan 17.

PMID:
22249355
2.

Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder.

Perlis RH, Fijal B, Adams DH, Sutton VK, Trivedi MH, Houston JP.

Biol Psychiatry. 2009 May 1;65(9):785-91. doi: 10.1016/j.biopsych.2008.10.002. Epub 2008 Dec 18.

PMID:
19095219
3.

Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale.

Sheehan DV, Harnett-Sheehan K, Spann ME, Thompson HF, Prakash A.

Int Clin Psychopharmacol. 2011 Mar;26(2):75-83. doi: 10.1097/YIC.0b013e328341bb5f.

PMID:
21102344
4.

Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.

Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I.

Eur Neuropsychopharmacol. 2004 Dec;14(6):457-70.

PMID:
15589385
5.

Duloxetine efficacy for major depressive disorder in male vs. female patients: data from 7 randomized, double-blind, placebo-controlled trials.

Kornstein SG, Wohlreich MM, Mallinckrodt CH, Watkin JG, Stewart DE.

J Clin Psychiatry. 2006 May;67(5):761-70.

PMID:
16841626
6.

Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder.

Coric V, Feldman HH, Oren DA, Shekhar A, Pultz J, Dockens RC, Wu X, Gentile KA, Huang SP, Emison E, Delmonte T, D'Souza BB, Zimbroff DL, Grebb JA, Goddard AW, Stock EG.

Depress Anxiety. 2010 May;27(5):417-25. doi: 10.1002/da.20695.

PMID:
20455246
7.

Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression.

Shelton RC, Prakash A, Mallinckrodt CH, Wohlreich MM, Raskin J, Robinson MJ, Detke MJ.

Int J Clin Pract. 2007 Aug;61(8):1337-48. Review.

PMID:
17627710
8.
9.

Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response.

Binder EB, Owens MJ, Liu W, Deveau TC, Rush AJ, Trivedi MH, Fava M, Bradley B, Ressler KJ, Nemeroff CB.

Arch Gen Psychiatry. 2010 Apr;67(4):369-79. doi: 10.1001/archgenpsychiatry.2010.18.

PMID:
20368512
10.

Association of catechol-O-methyltransferase variants with duloxetine response in major depressive disorder.

Houston JP, Kohler J, Ostbye KM, Heinloth A, Perlis RH.

Psychiatry Res. 2011 Oct 30;189(3):475-7. doi: 10.1016/j.psychres.2011.07.002. Epub 2011 Jul 24.

PMID:
21788083
11.

Duloxetine for major depressive disorder and daytime and nighttime hot flashes associated with the menopausal transition.

Freeman MP, Hirschberg AM, Wang B, Petrillo LF, Connors S, Regan S, Joffe H, Cohen LS.

Maturitas. 2013 Jun;75(2):170-4. doi: 10.1016/j.maturitas.2013.03.007. Epub 2013 Apr 17.

PMID:
23602542
12.

Duloxetine: a review of its use in the treatment of generalized anxiety disorder.

Carter NJ, McCormack PL.

CNS Drugs. 2009;23(6):523-41. doi: 10.2165/00023210-200923060-00006. Review.

PMID:
19480470
13.

Association of CRHR1 and CRHR2 with major depressive disorder and panic disorder in a Japanese population.

Ishitobi Y, Nakayama S, Yamaguchi K, Kanehisa M, Higuma H, Maruyama Y, Ninomiya T, Okamoto S, Tanaka Y, Tsuru J, Hanada H, Isogawa K, Akiyoshi J.

Am J Med Genet B Neuropsychiatr Genet. 2012 Jun;159B(4):429-36. doi: 10.1002/ajmg.b.32046. Epub 2012 Mar 29. Erratum in: Am J Med Genet B Neuropsychiatr Genet. 2013 Jan;162(1):78-85.

PMID:
22467522
14.

Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial.

Rynn M, Russell J, Erickson J, Detke MJ, Ball S, Dinkel J, Rickels K, Raskin J.

Depress Anxiety. 2008;25(3):182-9.

PMID:
17311303
15.

Brain-derived neurotrophic factor in generalized anxiety disorder: results from a duloxetine clinical trial.

Ball S, Marangell LB, Lipsius S, Russell JM.

Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jun 3;43:217-21. doi: 10.1016/j.pnpbp.2013.01.002. Epub 2013 Jan 10.

PMID:
23313564
16.

Interaction between CRHR1 and BDNF genes increases the risk of recurrent major depressive disorder in Chinese population.

Xiao Z, Liu W, Gao K, Wan Q, Yang C, Wang H, Wang X, Wang G, Liu Z.

PLoS One. 2011;6(12):e28733. doi: 10.1371/journal.pone.0028733. Epub 2011 Dec 14.

18.

Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.

Wohlreich MM, Mallinckrodt CH, Prakash A, Watkin JG, Carter WP.

Depress Anxiety. 2007;24(1):41-52.

PMID:
16845641
19.

Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders.

Liu Z, Zhu F, Wang G, Xiao Z, Tang J, Liu W, Wang H, Liu H, Wang X, Wu Y, Cao Z, Li W.

Neurosci Lett. 2007 Mar 6;414(2):155-8. Epub 2006 Dec 15.

PMID:
17258395
20.

Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.

Brannan SK, Mallinckrodt CH, Brown EB, Wohlreich MM, Watkin JG, Schatzberg AF.

J Psychiatr Res. 2005 Jan;39(1):43-53.

PMID:
15504423

Supplemental Content

Support Center